{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-023080","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.698049+00:00","generated_at":"2026-06-05T06:41:44.023375+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xenon Pharma reports FY2023 net loss $182.4M, cash $930.9M; XEN1101 Phase 3 on track","bullets":["Net loss of $44.7M in Q4 2023 and $182.4M for FY2023, vs $37.4M and $125.4M in 2022.","R&D expenses $41.1M in Q4, $167.5M for FY2023, driven by XEN1101 Phase 3 epilepsy trials.","Cash and marketable securities $930.9M as of Dec 31, 2023; expected runway into 2027.","X-TOLE2 Phase 3 epilepsy patient enrollment expected to complete late 2024 to early 2025.","End-of-Phase 2 meeting with FDA for XEN1101 in major depressive disorder planned in April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-023080","json":"https://secwatch.observer/filing/0000950170-24-023080.json","markdown":"https://secwatch.observer/filing/0000950170-24-023080.md","text":"https://secwatch.observer/filing/0000950170-24-023080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024023080/0000950170-24-023080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024023080/xene-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:41:44.023375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc633bc7b1c140e9ce5e10c77a19af5582cfeff2","claim":"Xenon Pharmaceuticals Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024023080/0000950170-24-023080-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}